Tositumomab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade from ProteoGenix; catalogue PX-TA1101; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Introduction to Tositumomab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade Tositumomab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade is a monoclonal antibody that targets the CD20 protein, which is found on the surface of B cells. This biosimilar is a highly specific and potent therapeutic agent that has been developed for the treatment of various B cell malignancies, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. In this article, we will explore the structure, activity, and potential applications of Tositumomab Biosimilar in the field of cancer research.
Structure of Tositumomab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade Tositumomab Biosimilar is a biosimilar version of the FDA-approved drug, Tositumomab. It is a recombinant humanized monoclonal antibody that is designed to mimic the structure and function of the original drug. The antibody is composed of two heavy chains and two light chains, which are linked together by disulfide bonds. The variable regions of the antibody, also known as the antigen-binding domains, are responsible for the specific binding to the CD20 protein on B cells.
Activity of Tositumomab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade Tositumomab Biosimilar works by binding to the CD20 protein on the surface of B cells, leading to their destruction through various mechanisms. The binding of the antibody to CD20 triggers the immune system to attack and kill the cancerous B cells. Additionally, the antibody can also activate the complement system, which is a part of the immune system that helps in the destruction of cancer cells. This dual mechanism of action makes Tositumomab Biosimilar a potent and effective therapeutic agent for B cell malignancies.
Potential Applications of Tositumomab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade The primary application of Tositumomab Biosimilar is in the treatment of B cell malignancies, particularly non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. It is used as a single agent or in combination with other chemotherapy drugs to improve treatment outcomes. The biosimilar has shown promising results in clinical trials, with high response rates and improved survival rates in patients with B cell malignancies.
Apart from its use in cancer treatment, Tositumomab Biosimilar also has potential applications in the field of research. The antibody can be used as a tool to study the role of CD20 in B cell development and function. It can also be used to investigate the mechanisms of action of other CD20-targeted therapies and to develop new treatment strategies for B cell malignancies.
In conclusion, Tositumomab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade is a highly specific and potent monoclonal antibody that targets the CD20 protein on B cells. Its unique structure and dual mechanism of action make it an effective therapeutic agent for the treatment of B cell malignancies. With its potential applications in cancer treatment and research, Tositumomab Biosimilar has the potential to improve the lives of patients with B cell malignancies and contribute to further advancements in the field of cancer research.
ProteoGenix catalogue number PX-TA1101. For research use only.
Target: Tositumomab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Tositumomab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
